In-Situ Cancer Vaccine: Phase I/IIb, Open-Label Study to Assess the Safety of AlloStim in Combination With Cryoablation as Third Line Therapy for Metastatic Colorectal Cancer

Trial Profile

In-Situ Cancer Vaccine: Phase I/IIb, Open-Label Study to Assess the Safety of AlloStim in Combination With Cryoablation as Third Line Therapy for Metastatic Colorectal Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2016

At a glance

  • Drugs T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Immunovative Therapies
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Nov 2016 According to an Immunovative Therapies media release, first volunteers has been dosed with initial vaccine doses. Enrollment is expected to be completed by the end of July 2017.
    • 19 Oct 2016 Planned End Date changed from 1 Nov 2018 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top